FEB 0 6 2013

# A BILL FOR AN ACT

RELATING TO HEALTH.

#### BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF HAWAII:

| 1  | SECTION 1. Chapter 453, Hawaii Revised Statutes, is             |
|----|---|
| 2  | amended by adding a new part to be appropriately designated and |
| 3  | to read as follows:   |
| 4  | "PART . EXPEDITED PARTNER THERAPY                               |
| 5  | §453-A Definitions. As used in this part:                       |
| 6  | "Expedited partner therapy" means the indirect treatment of     |
| 7  | partners of a patient who has been diagnosed as having a        |
| 8  | sexually transmitted disease through the dispensing or          |
| 9  | prescribing of antibiotic therapy for the treatment of the      |
| 10 | partners to the patient without the physical examination of the |
| 11 | partners by a health professional.                              |
| 12 | "Health professional" means any of the following:               |
| 13 | (1) A person licensed or otherwise authorized by law to         |
| 14 | practice medicine or surgery under this chapter and             |
| 15 | whose scope of practice includes the diagnosis and              |
| 16 | treatment of sexually transmitted diseases; or                  |
| 17 | (2) For the purpose of dispensing antibiotic therapy under      |
| 18 | this section, a pharmacist who is licensed or                   |
|    | 2013-1031 SB655 SD1 SMA.doc                                     |

| 1  | otherwise authorized to engage in the practice of                |
|----|--|
| 2  | pharmacy under chapter 461.                                      |
| 3  | "Sexual activity" means sexual intercourse, cunnilingus,         |
| 4  | fellatio, anal intercourse, or any other intrusion, however      |
| 5  | slight, of any part of a person's body or of any object into the |
| 6  | genital or anal openings of another person's body, but emission  |
| 7  | of semen is not required.  |
| 8  | "Sexually transmitted disease" means any sexually                |
| 9  | transmitted disease recommended by the Centers for Disease       |
| 10 | Control and Prevention for expedited partner therapy, including  |
| 11 | but not limited to chlamydia, gonorrhea, and human               |
| 12 | immunodeficiency virus.  |
| 13 | §453-B Expedited partner therapy. (a) A health                   |
| 14 | professional may in addition to treating a patient, provide      |
| 15 | expedited partner therapy to the partners of the patient if all  |
| 16 | of the following requirements are met:                           |
| 17 | (1) The patient has a laboratory-confirmed or suspected          |
| 18 | clinical diagnosis of a sexually transmitted disease;            |
| 19 | (2) The patient indicates that the patient has partners          |
| 20 | with whom the patient has engaged in sexual activity             |
| 21 | within the sixty-day period immediately preceding the            |
| 22 | diagnosis of a sexually transmitted disease; and                 |

15

16

17

18

19

20

| 1          | (3) | The patient indicates that the patient's partners are |
|------------|-----|---|
| 2          |     | unable or unlikely to seek clinical services in a     |
| 3          |     | timely manner.  |
| <b>4</b> · | (b) | A health professional who provides expedited partner  |

- 4 (b) A health professional who provides expedited partner
  5 therapy as authorized in this section shall do all of the
  6 following:
- 7 Dispense or prescribe antibiotic therapy in the name (1) 8 of the partners, if known, without the physical 9 examination of the partners by the health 10 professional. Notwithstanding any law to the 11 contrary, if the name of the partners are not known, 12 the health professional shall dispense or prescribe 13 the antibiotic therapy in the name of "Expedited 14 Partner Therapy";
  - (2) Convey to the patient that it is important to notify the patient's partners of the patient's diagnosis and that it is important for the partners to obtain medical care for a complete evaluation, testing for sexually transmitted diseases, counseling, and treatment; and
- 21 (3) Distribute to the patient the information sheet 22 developed pursuant to section 453-C.

| 1  | <b>§453</b> | -C Information sheet. The department of health shall   |
|----|-------------|--|
| 2  | develop a   | nd, upon request, distribute to health professionals   |
| 3  | subject t   | o this part an information sheet that includes all of  |
| 4  | the follo   | wing:  |
| 5  | (1)         | A description of expedited partner therapy and its     |
| 6  |             | purpose;   |
| 7  | (2)         | A notice that an individual who has been treated for a |
| 8  |             | sexually transmitted disease should be retested after  |
| 9  | ,           | treatment to detect possible persistent or recurrent   |
| 10 |             | infection, including information on the timing of      |
| 11 |             | retesting, as recommended by the Centers for Disease   |
| 12 |             | Control and Prevention;                                |
| 13 | . (3)       | A warning about the possible dangers of administering  |
| 14 |             | antibiotic therapy to a pregnant individual;           |
| 15 | (4)         | Information about antibiotics dispensed or prescribed  |
| 16 |             | and dosages of those antibiotics dispensed or          |
| 17 |             | prescribed, as recommended by the Centers for Disease  |
| 18 |             | Control and Prevention;                                |
| 19 | (5)         | A warning about the risk of allergies to and drug      |
| 20 |             | interactions with the antibiotics described in         |
| 21 |             | paragraph (4);   |

| 1  | (6)          | Information about sexually transmitted diseases, the   |
|----|--------------|--|
| 2  |              | treatment of sexually transmitted diseases, and the    |
| 3  |              | prevention of sexually transmitted diseases;           |
| 4  | (7)          | A notice that the patient and the patient's partners   |
| 5  |              | should abstain from sexual activity for seven days     |
| 6  |              | after the patient and the partners have completed the  |
| 7  |              | antibiotic therapy;                                    |
| 8  | (8)          | A notice that the partners should be tested for        |
| 9  |              | sexually transmitted diseases;                         |
| 10 | (9)          | A notice of the risk to the patient, the partners, and |
| 11 |              | others, including the public health, if a sexually     |
| 12 |              | transmitted disease is not completely treated;         |
| 13 | (10)         | A notice of the responsibility of the patient to       |
| 14 |              | notify sexual partners of the risk of sexually         |
| 15 |              | transmitted diseases and the importance of examination |
| 16 |              | and treatment for sexually transmitted diseases; and   |
| 17 | (11)         | A statement advising any individual who has any        |
| 18 |              | questions regarding anything in the information sheet  |
| 19 |              | to contact a health professional or the department of  |
| 20 |              | health.  |
| 21 | § <b>453</b> | -D Limitation of liability. A health care              |
| 22 | profession   | nal who provides expedited partner therapy as          |
|    | 2013-1031    | SB655 SD1 SMA.doc                                      |

- 1 authorized under section 453-B shall not be subject to
- 2 prosecution in a criminal proceeding, liable for damages in a
- 3 civil action, or subject to disciplinary action under sections
- 4 453-8 and 453-8.2 for personal injury, death, or other
- 5 consequences arising from or related in any way to the provision
- 6 of expedited partner therapy by the health care professional;
- 7 provided that this section shall not apply if the action of the
- 8 health care professional in providing expedited partner therapy
- 9 is gross negligence."
- 10 SECTION 2. Section 328-16, Hawaii Revised Statutes, is
- 11 amended as follows:
- 1. By amending subsections (a), (b), and (c) to read:
- "(a) A prescription drug shall be dispensed only if its
- 14 label bears the following:
- 15 (1) The name, business address, and telephone number of
- 16 the seller. The business address shall be the
- 17 physical location of the pharmacy or the dispensing
- 18 practitioner's office;
- 19 (2) [The] Except as otherwise authorized for expedited
- partner therapy in section 453-B, the name of the
- 21 person for whom the drug was prescribed or the name of

| 1  |      | the owner of the animal for which the drug was         |
|----|------|--|
| 2  |      | prescribed;  |
| 3  | (3)  | The serial number of the prescription;                 |
| 4  | (4)  | The date the prescription was prepared;                |
| 5  | (5)  | The name of the practitioner if the seller is not the  |
| 6  |      | practitioner;  |
| 7  | (6)  | The name, strength, and quantity of the drug;          |
| 8  | (7)  | The "use by" date for the drug, which shall be:        |
| 9  |      | (A) The expiration date on the manufacturer's          |
| 10 |      | container; or  |
| 11 |      | (B) One year from the date the drug is dispensed,      |
| 12 |      | whichever is earlier;                                  |
| 13 | (8)  | The number of refills available, if any;               |
| 14 | (9)  | In the case of the dispensing of an equivalent generic |
| 15 |      | drug product, the statement "same as (brand name of    |
| 16 |      | the drug product prescribed or the referenced listed   |
| 17 |      | drug name)", or words of similar meaning; and          |
| 18 | (10) | Specific directions for the drug's use; provided that  |
| 19 |      | if the specific directions for use are too lengthy for |
| 20 |      | inclusion on the label, the notation "take according   |
| 21 |      | to written instructions" may be used if separate       |
| 22 |      | written instructions for use are actually issued with  |

| I  |            | the drug by the practitioner of the pharmacist, but in                     |
|----|------------|--|
| 2  | :          | no event shall the notation "take as directed",                            |
| 3  |            | referring to oral instructions, be considered                              |
| 4  | ,          | acceptable.  |
| 5  | If any pre | scription for a drug does not indicate the number of                       |
| 6  | times it m | ay be refilled, if any, the pharmacist shall not                           |
| 7  | refill tha | t prescription unless subsequently authorized to do so                     |
| 8  | by the pra | ctitioner. The act of dispensing a prescription drug                       |
| 9  | other than | a professional sample or medical oxygen contrary to                        |
| 10 | this subse | ction shall be deemed to be an act that results in a                       |
| 11 | drug being | misbranded while held for sale.  |
| 12 | (d)        | In addition to the requirements enumerated in                              |
| 13 | subsection | (a), a prescription drug shall be dispensed only:                          |
| 14 | (1)        | By a pharmacist pursuant to a valid prescription $[rac{\Theta 	au}{2}]$ , |
| 15 |            | section 461-1[+], or section 453-B;  |
| 16 | (2)        | By a medical oxygen distributor pursuant to a                              |
| 17 |            | prescription or certificate of medical necessity;                          |
| 18 |            | provided that the drug to be dispensed is medical                          |
| 19 |            | oxygen; or   |
| 20 | (3)        | By a practitioner to an ultimate user; provided that:                      |
| 21 |            | (A) [The] Except as otherwise authorized for                               |
| 22 |            | expedited partner therapy in section 453-B, the                            |

### S.B. NO. 655 S.D. 1

| 1  | practitioner shall inform the patient, prior to   |
|----|---|
| 2  | dispensing any drug other than a professional     |
| 3  | sample, that the patient may have a written,      |
| 4  | orally ordered, or electronically transmitted or  |
| 5  | conveyed prescription directed to a pharmacy or a |
| 6  | medical oxygen distributor of the patient's own   |
| 7  | choice;   |
| 8  | (B) The practitioner shall promptly record in the |
| 9  | practitioner's records:                           |
| 10 | (i) The prescription in full;                     |
| 11 | (ii) The name, strength, and quantity of the      |
| 12 | drug, and specific directions for the drug's      |
| 13 | use;  |
| 14 | (iii) The date the drug was dispensed; [and]      |
| 15 | (iv) [The] Except as otherwise authorized for     |
| 16 | expedited partner therapy in section 453-B,       |
| 17 | the name and address of the person for whom       |
| 18 | the drug was prescribed or the name of the        |
| 19 | owner of the animal for which the drug was        |
| 20 | prescribed; and                                   |
|    |   |

| T  |            |       | (V) Prescription drugs dispensed or prescribed     |
|----|------------|-------|--|
| 2. |            |       | for expedited partner therapy as authorized        |
| 3  |            |       | under section 453-B.                               |
| 4  |            | (C)   | The records described in subparagraph (B) shall    |
| 5  |            |       | be subject to the inspection of the department or  |
| 6  |            |       | its agents at all times; and                       |
| 7  |            | (D)   | No undisclosed rebate, refund, commission,         |
| 8  |            |       | preference, discount, or other consideration,      |
| 9  |            |       | whether in the form of money or otherwise, has     |
| 10 |            |       | been offered to the practitioner as compensation   |
| 11 |            |       | or inducement to dispense or prescribe any         |
| 12 |            |       | specific drug in preference to other drugs that    |
| 13 |            |       | might be used for the identical therapeutic        |
| 14 |            |       | indication.  |
| 15 | (c)        | A pre | escription may be communicated in writing, orally, |
| 16 | or by elec | ctron | ic transmission, and shall include the following   |
| 17 | informatio | on:   |  |
| 18 | (1)        | The a | authorization of the practitioner noted as         |
| 19 |            | follo | ows:   |
| 20 |            | (A)   | Written prescriptions shall include the original   |
| 21 |            |       | signature of the practitioner;                     |

## S.B. NO. 655 S.D. 1

| 1  |     | (B) Oral  | prescriptions shall be promptly recorded by             |
|----|-----|-----------|---|
| 2  |     | the       | pharmacist or medical oxygen distributor and            |
| 3  |     | shal      | l include the practitioner's oral code                  |
| 4  |     | desi      | gnation; and  |
| 5  |     | (C) Elec  | tronic prescriptions shall be irrefutably               |
| 6  |     | trac      | eable to the prescribing practitioner by a              |
| 7  |     | reco      | gnizable and unique practitioner identifier             |
| 8  |     | such      | as:   |
| 9  |     | (i)       | A bitmap or graphic image of the                        |
| 10 |     |           | prescriber's handwritten signature and the              |
| 11 |     |           | prescriber's oral code designation (or                  |
| 12 |     |           | license number or other identifier if the               |
| 13 |     |           | <pre>prescriber is an out-of-state practitioner);</pre> |
| 14 |     | (ii)      | An electronic signature;                                |
| 15 |     | (iii)     | A digital signature; or                                 |
| 16 |     | (iv)      | By other means as approved by the director;             |
| 17 | (2) | The date  | of issuance;  |
| 18 | (3) | The pract | itioner's name, business telephone number,              |
| 19 |     | and busin | ess address, unless the practitioner is                 |
| 20 |     | otherwise | uniquely identified and the pharmacy or                 |
| 21 |     | medical c | xygen distributor dispensing the prescription           |

| 1  |     | has the prescriber's contact information on fire       |
|----|-----|--|
| 2  |     | accessible within the dispensing area;                 |
| 3  | (4) | The name, strength, and quantity of the drug to be     |
| 4  |     | dispensed, and specific directions for the drug's use; |
| 5  | (5) | [The] Except as otherwise authorized for expedited     |
| 6  |     | partner therapy in section 453-B, the name and address |
| 7  |     | of the person for whom the prescription was written or |
| 8  |     | the name of the owner of the animal for which the drug |
| 9  |     | was prescribed, unless the pharmacy or medical oxygen  |
| 10 |     | distributor dispensing the prescription has the        |
| 11 |     | address on file accessible within the dispensing area; |
| 12 | (6) | The room number and route of administration, if the    |
| 13 |     | patient is in an institutional facility; and           |
| 14 | (7) | The number of allowable refills, if the prescription   |
| 15 |     | is refillable. If the number of refills authorized by  |
| 16 |     | the practitioner is indicated using the terms "as      |
| 17 |     | needed" or "prn", the prescription may be refilled up  |
| 18 |     | to twelve months from the date the original            |
| 19 |     | prescription was written. After the twelve-month       |
| 20 |     | period, the "as needed" or "prn" prescription may be   |
| 21 |     | refilled for a subsequent three-month period;          |
| 22 |     | provided:  |

2013-1031 SB655 SD1 SMA.doc

| 1  | (A)            | The prescription is refilled only once during the |
|----|----------------|---|
| 2  |                | three-month period;                               |
| 3  | (B)            | The refill does not exceed a thirty-day supply of |
| 4  |                | the drug;   |
| 5  | (C)            | The refill does not provide any amount of the     |
| 6  |                | drug fifteen months beyond the date the original  |
| 7  |                | prescription was written;                         |
| 8  | (D)            | In the case of medical oxygen, the duration of    |
| 9  |                | therapy indicated on a certificate of medical     |
| 10 |                | necessity shall supersede any limitations or      |
| 11 |                | restrictions on refilling; and                    |
| 12 | (E)            | Subparagraphs (A) to (D) shall apply only to      |
| 13 |                | pharmacies and medical oxygen distributors        |
| 14 |                | practicing in the State."                         |
| 15 | 2. By am       | ending subsection (g) to read:                    |
| 16 | "(g) Any       | drug other than medical oxygen dispensed pursuant |
| 17 | to a prescript | ion shall be exempt from the requirements of      |
| 18 | section 328-15 | (except paragraphs (1), (9), (11), and (12), and  |
| 19 | the packaging  | requirements of paragraphs (7) and (8)), if the   |
| 20 | drug bears a l | abel containing:                                  |
| 21 | (1) The        | name and address of the pharmacy;                 |

```
The serial number and the date of the prescription or
1
         (2)
              of its filling;
2
              The name of the practitioner;
3
         (3)
         (4) [The] Except as otherwise authorized for expedited
4
              partner therapy in section 453-B, the name of the
5
6
              patient;
         (5) The directions for use; and
7
              Any cautionary statements contained in the
8
         (6)
9
              prescription.
10
    This exemption shall not apply to any drug dispensed in the
    course of the conduct of a business of dispensing drugs pursuant
11
    to diagnosis by mail, or to a drug dispensed in violation of
12
13
    subsection (a), (b), (c), or (d)."
14
         SECTION 3. Section 328-17.6, Hawaii Revised Statutes, is
    amended as follows:
15
16
         1. By amending subsections (c) and (d) to read:
         "(c) Any pharmacist or medical oxygen distributor who
17
    fills or refills a prescription from an out-of-state
18
    practitioner shall:
19
         (1) Note the following on the prescription record:
20
              out-of-state practitioner's full name, address, and
21
```

2013-1031 SB655 SD1 SMA.doc

telephone number;

22

| 1  | (2)   | Be responsible for validating and verifying the        |
|----|---|--|
| 2  |   | practitioner's prescriptive authority by virtue of a   |
| 3  |   | valid out-of-state license, a Drug Enforcement         |
| 4  |   | Administration registration number, or other measures  |
| 5  |   | as appropriate; and                                    |
| 6  | (3)   | [Demand] Except as otherwise authorized for expedited  |
| 7  |   | partner therapy in section 453-B, demand proper        |
| 8  |   | identification from the person whose name appears on   |
| 9  |   | the prescription prior to filling the prescription, in |
| 10 |   | addition to complying with any identification          |
| 11 |   | procedures established by the department for filling   |
| 12 |   | and refilling an out-of-state prescription.            |
| 13 | (d)   | Before refilling a transferred out-of-state            |
| 14 | prescription, a pharmacist or medical oxygen distributor shall: |  |
| 15 | (1)   | [Advise] Except as otherwise authorized for expedited  |
| 16 |   | partner therapy in section 453-B, advise the person    |
| 17 |   | whose name appears on the prescription that the        |
| 18 |   | prescription on file at the originating out-of-state   |
| 19 |   | pharmacy or medical oxygen distributor may be          |
| 20 |   | canceled; and  |
| 21 | (2)   | Record all information required to be on a             |
| 22 |   | prescription, including:                               |

2013-1031 SB655 SD1 SMA.doc

| 1  | (A)            | The date of issuance of the original               |
|----|----------------|--|
| 2  |                | prescription;                                      |
| 3  | (B)            | The number of refills authorized on the original   |
| 4  |                | prescription;                                      |
| 5  | (C)            | The date the original prescription was dispensed;  |
| 6  | (D)            | The number of valid refills remaining and the      |
| 7  |                | date of the last refill;                           |
| 8  | (E)            | The out-of-state pharmacy's or out-of-state        |
| 9  |                | medical oxygen distributor's name, telephone       |
| 10 |                | number, and address, and the original              |
| 11 |                | prescription number or control number from which   |
| 12 |                | the prescription information was transferred; and  |
| 13 | (F)            | The name of the transferor pharmacist or the       |
| 14 |                | medical oxygen distributor's agent."               |
| 15 | 2. By am       | ending subsection (f) to read:                     |
| 16 | "(f) An        | out-of-state prescription record shall state the   |
| 17 | date of fillin | g or refilling and, except as otherwise authorized |
| 18 | for expedited  | partner therapy in section 453-B, the local        |
| 19 | address of the | person whose name appears on the prescription."    |
| 20 | SECTION 4      | . Section 328-17.7, Hawaii Revised Statutes, is    |
| 21 | amended by ame | nding subsection (a) to read as follows:           |

| 1  | "(a)       | Every practitioner, pharmacist, or medical oxygen      |
|----|------------|--|
| 2  | distributo | or who compounds, sells, or delivers any prescribed    |
| 3  | drug to a  | patient or a patient's agent shall maintain records    |
| 4  | that ident | cify:  |
| 5  | (1)        | The specific drug product dispensed, including:        |
| 6  |            | (A) The product's national drug code (NDC) number; or  |
| 7  |            | (B) The brand name or the established name and the     |
| 8  |            | name or commonly accepted abbreviation of the          |
| 9  | •          | principal labeler of the drug product dispensed,       |
| 10 |            | the product strength, and the dosage form;             |
| 11 | (2)        | The quantity of the drug;                              |
| 12 | (3)        | Directions for use;                                    |
| 13 | (4)        | The number of allowable refills;                       |
| 14 | (5)        | The date of initial dispensing and the dates of all    |
| 15 |            | refilling;   |
| 16 | (6)        | The date of any transfer of the prescription;          |
| 17 | (7)        | The name, business address, and telephone number of    |
| 18 |            | the recipient pharmacist or medical oxygen distributor |
| 19 |            | for any transfer of prescription;                      |
| 20 | (8)        | The prescribing practitioner, including name, business |
| 21 |            | address, and telephone number;                         |

```
1
         (9)
              The format (oral, written, or electronic) in which the
              prescription was received;
2
3
        (10)
              [The] Except as otherwise authorized for expedited
4
              partner therapy in section 453-B, the patient,
5
              including name, address, and telephone number;
              The date of prescribing; and
6
        (11)
7
              The name of the practitioner, pharmacist, or medical
        (12)
8
              oxygen distributor dispensing the drug.
9
    Every prescription dispensed shall have the name of the
10
    pharmacist, dispensing practitioner, or medical oxygen
11
    distributor responsible for the dispensing appended to the
12
    prescription record, and every prescription record shall be
13
    preserved and legible for a period of not less than five years.
14
    The prescription records shall be subject at all times to the
15
    inspection of the director of health or the director's agent."
16
         SECTION 5. In codifying the new sections added by section
17
    1 of this Act, the revisor of statutes shall substitute
18
    appropriate section numbers for the letters used in designating
19
    the new sections in this Act.
20
         SECTION 6. Statutory material to be repealed is bracketed
21
    and stricken. New statutory material is underscored.
```

This Act shall take effect upon its approval.

2013-1031 SB655 SD1 SMA.doc

SECTION 7.

22

### Report Title:

Medicine and Surgery; Sexually Transmitted Diseases; Expedited Partner Therapy; Prescription Drugs; Labeling; Record Keeping

#### Description:

Allows health care professionals, subject to certain requirements, to treat the partners of patients diagnosed as having a sexually transmitted disease recommended by the Centers for Disease Control and Prevention for expedited partner therapy, such as chlamydia, by dispensing or prescribing medication to the partners without examining the partners. Provides protection from criminal liability, legal liability, and disciplinary action for health care professionals who provide expedited partner therapy as authorized. Requires the department of health to develop an information sheet about sexually transmitted diseases for use by health care professionals who provide expedited partner therapy. Creates exceptions to prescription drug labeling and reporting requirements for expedited partner therapy. (SD1)

The summary description of legislation appearing on this page is for informational purposes only and is not legislation or evidence of legislative intent.